ReviewJournal of clinical medicine2025
COPD and Cardiovascular Diseases: Biomarker-Guided Stratification and Therapeutic Perspectives.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Developing and validating the CE-MACE model to predict 1-year major adverse cardiovascular events post-COPD exacerbation using routine healthcare data.The European respiratory journal · 2026Article
- Cardiovascular Risk During the 90-Day Vulnerable Window After COPD Exacerbations: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Associations between physical activity and mortality in chronic obstructive pulmonary disease population with comorbidities: a prospective cohort.Journal of thoracic disease · 2026Article
- The Disproportionate Burden of Cardiovascular Disease in Mild-to-Moderate COPD.International journal of chronic obstructive pulmonary disease · 2026Article
- Global Incidence of Cardiovascular Diseases Attributable to Chronic Obstructive Pulmonary Disease: A Modelling Study Based on GBD 2021.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a progressive and preventable respiratory disorder associated with a significantly increased risk of cardiovascular disease (CVD), including ischemic heart disease, heart failure, pulmonary hypertension, and arrhythmias. The association is bidirectional, with CVD adversely affecting COPD prognosis and vice versa. Beyond shared risk factors such as smoking, aging, and socioeconomic status, COPD itself, through mechanisms including systemic inflammation, oxidative stress, hypoxia, and hyperinflation, contributes independently to cardiovascular morbidity and mortality. Recent research has focused on identifying circulating biomarkers that can aid in early detection, risk stratification, and treatment optimization for patients at risk of both conditions. This review summarizes current evidence on the pathophysiological mechanisms linking COPD and CVD, highlights emerging biomarkers with potential prognostic utility for major adverse cardiovascular events (MACE) and all-cause mortality, and it discusses clinical and research implications for biomarker-guided, personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.